Fasciola hepatica Infection in an Indigenous Community of the Peruvian Jungle

Cabada, Miguel M.; Castellanos-González, Alejandro; López, Martha; Caravedo, Maria A.; Arque, Eulogia; White, A. Clinton

doi:10.4269/ajtmh.15-0769

Cited by 7 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[42][43][44][45][46] Reports of fascioliasis emerging in new areas within endemic countries suggest that significant work is still needed to describe the distribution and burden of the infection. 47,48 An important characteristic of Fasciola's epidemiology is its patchy geographic distribution. The prevalence of Fasciola infection can vary widely within small geographic areas.…”

Section: Epidemiologymentioning

confidence: 99%

See 1 more Smart Citation

<p>Human Fascioliasis: Current Epidemiological Status and Strategies for Diagnosis, Treatment, and Control</p>

Caravedo¹,

Cabada²

2020

RRTM

View full text Add to dashboard Cite

Purpose of the Review: This review aims to critically assess current knowledge about the epidemiology, diagnosis, and management of Fasciola infection in humans. Recent Findings: Fascioliasis is an emerging neglected zoonotic infection affecting the health and wellbeing of human populations. The burden of infection is unclear, and studies have shown the geographic expansion of fascioliasis in human and livestock likely related to climate change. The infection can be asymptomatic or present in acute or chronic forms. Regardless of the presentation, fascioliasis can be associated with long-term complications such as anemia and malnutrition. Early in the infection, antibody testing is the only tool available for diagnosis confirmation. In the chronic forms serology and stool microscopy are helpful. Other tests such as antigen detection and PCR-based methods including isothermal tests have shown promising results. Triclabendazole is the only drug available to treat Fasciola infection. However, reports of resistant infections in livestock and human threaten the clinical care and control of the infection in endemic areas. Summary: Fascioliasis is an emerging infection around the world with an uncertain burden. Lack of standardization of diagnostic testing and treatment alternatives hinder treatment and control of the infection.

show abstract

Section: Epidemiologymentioning

confidence: 99%

“… 42–46 Reports of fascioliasis emerging in new areas within endemic countries suggest that significant work is still needed to describe the distribution and burden of the infection. 47 , 48 …”

Section: Epidemiologymentioning

confidence: 99%

<p>Human Fascioliasis: Current Epidemiological Status and Strategies for Diagnosis, Treatment, and Control</p>

Caravedo¹,

Cabada²

2020

RRTM

View full text Add to dashboard Cite

show abstract

“…This phenomenon of double resistance compromises the idea of combined drug treatments. More recently, TCBZ resistance in humans has been reported in Chile and Peru [ 14 , 15 ]. There is a pressing need to understand epidemiological and mechanistic aspects of drug resistance emergence.…”

Section: Introductionmentioning

confidence: 99%

Pleiotropic alterations in gene expression in Latin American Fasciola hepatica isolates with different susceptibility to drugs

et al. 2018

View full text Add to dashboard Cite

BackgroundFasciola hepatica is the main agent of fasciolosis, a zoonotic disease affecting livestock worldwide, and an emerging food-borne disease in humans. Even when effective treatments are available, drugs are costly and can result in tolerance, liver damage and normally they do not prevent reinfection. Drug-resistant strains in livestock have been reported in various countries and, more worryingly, drug resistance in human cases has emerged in South America. The present study aims to characterize the transcriptome of two South American resistant isolates, the Cajamarca isolate from Peru, resistant to both triclabendazole and albendazole (TCBZR/ABZR) and the Rubino isolate from Uruguay, resistant to ABZ (TCBZS/ABZR), and compare them to a sensitive strain (Cenapa, Mexico, TCBZS/ABZS) to reveal putative molecular mechanisms leading to drug resistance.ResultsWe observed a major reduction in transcription in the Cajamarca TCBZR/ABZR isolate in comparison to the other isolates. While most of the differentially expressed genes are still unannotated, several trends could be detected. Specific reduction in the expression levels of cytoskeleton proteins was consistent with a role of tubulins as putative targets of triclabendazole (TCBZ). A marked reduction of adenylate cyclase might be underlying pleiotropic effects on diverse metabolic pathways of the parasite. Upregulation of GST mu isoforms suggests this detoxifying mechanism as one of the strategies associated with resistance.ConclusionsOur results stress the value of transcriptomic approaches as a means of providing novel insights to advance the understanding of drug mode of action and drug resistance. The results provide evidence for pleiotropic variations in drug-resistant isolates consistent with early observations of TCBZ and ABZ effects and recent proteomic findings.Electronic supplementary materialThe online version of this article (10.1186/s13071-017-2553-2) contains supplementary material, which is available to authorized users.

show abstract

Fascioliasis

Pineda-Reyes,

Cabada

2025

Treatment and Management of Tropical Liver Disease

View full text Add to dashboard Cite

Fasciola hepatica Infection in an Indigenous Community of the Peruvian Jungle

Cited by 7 publications

References 19 publications

<p>Human Fascioliasis: Current Epidemiological Status and Strategies for Diagnosis, Treatment, and Control</p>

<p>Human Fascioliasis: Current Epidemiological Status and Strategies for Diagnosis, Treatment, and Control</p>

Pleiotropic alterations in gene expression in Latin American Fasciola hepatica isolates with different susceptibility to drugs

Fascioliasis

Contact Info

Product

Resources

About